Table 1 Exosomal circRNAs in non-small cell lung cancer
From: Emerging roles of exosomal circRNAs in non-small cell lung cancer
Research Subjects | Circular RNA | Effects | Targets or pathways | References |
|---|---|---|---|---|
Immortalized human bronchial epithelial cells (BEAS-2B), human lung cancer cell lines (A549, H460, H1299, H226, MES-1), NSCLC and matched normal adjacent tissue samples | Circ-SATB2 | Progression of NSCLC↑ | miR-326↓, FSCN1↑ | N.Zhang et al. (2020) [32] |
Tumor tissues, adjacent normal tissues, and blood samples, Human NSCLC cell lines (A549 and H1299) and bronchial epithelial cells (BEAS-2B) | Circ-0008717 | Cell tumorigenicity and angiogenesis in NSCLC↑ | miR-1287-5p↓, PAK2↑ | H.Wang et al. (2022) [160] |
Human NSCLC cell lines (A549, H1299, H460, H226, PC9), THP-1 cells | Circ-FARSA | NSCLC metastasis↑ | M2 macrophage polarization↑ PTEN/PI3K/AKT pathway↑ | T.Chen et al. (2021) [161] |
The human normal lung epithelial cell line HBE, human lung cancer cell lines (A549, PC9, 1650, and H1299) | Circ-SHKBP1 | Proliferation, migration, invasion, stemness of NSCLC cells↑ | miR-1294↓, PKM2 expression↑, glycolysis↑ | W.Chen et al. (2022) [162] |
Patient plasma, Normal lung cell BEAS-2B and NSCLC cell lines A549 and H292 | Circ-ARHGAP10 | Proliferation, migration, invasion, glycolysis of NSCLC cells↑ | miR-638↑, FAM83F↑ | K.Fang et al. (2022) [163] |
NSCLC tumors and their adjacent normal tissues, CALU3, CALU6, A549, H1229, H1975 cells | Circ-PLK1 | Malignant phenotype of NSCLC cells↑, the progression of NSCLC↑ | miR-1294↓, HMGA1↑ | C.Li et al. (2022) [164] |
Patient NSCLC tissues, cell lines HCC827 and H1975 | Circ-0002130 | Osimertinib-Resistance in NSCLC↑ | miR-498↓ | J.Ma et al. (2020) [165] |
NSCLC tissue samples, NSCLC cells (A549 and H1299), human bronchial epithelial cells (BEAS-2B) | Circ-0007385 | NSCLC proliferation and stemness↑ | miR-1253↓, FAM83A↑ | Z.Ning et al. (2022) [166] |
human HCC827, A549, H1755 and H1299, NSCLC cells and bronchial airway epithelial BEAS-2B cells (CRL-9609) | Circ-CD226 | NSCLC cell proliferation, migration, invasion, stemness↑ | miR-1224-3p↓, HMGA2↑ | L.Peng et al. (2022) [167] |
NSCLC tissues and blood samples, human normal bronchial epithelial cells (16HBE) and NSCLC cells (A549 and 1299) | Circ-PIP5K1A | Progression of NSCLC cells↓, cisplatin sensitivity↑ | miR-101↓, ABCC1↑ | N.Shao et al. (2021) [168] |
NSCLC tumor tissues, Human NSCLC cells (H1299, HCC827, PC9, and A549) and a normal bronchial epithelial cell line (BEAS-2B) | Circ-CCDC134 | NSCLC cell growth, metastasis, glycolysis↑ | miR-625-5p↓, NFAT5↑ | Z.Tong et al. (2023) [169] |
Tumor tissues, Human NSCLC cells (H1299 and A549) and bronchial epithelial cells (16HBE) | Circ-0002476 | NSCLC cell growth, invasion↑, mtDNA damage↓ | miR-1182↓, PAK2↑ | W.Wang et al.(2022) [170] |
NSCLC blood samples, NSCLC cells A549 and H1299 | Circ-ERBB2IP | Tumor growth in NSCLC↑ | miR-5195-3p↓, PSAT1↑ | X.Peng et al. (2023) [171] |
Human NSCLC cell lines (A549, H1299, H661, and SKMES-1), human normal bronchial epithelial cell line 16HBE, and human embryonic kidney cell line 293T | Circ-0008928 | CDDP sensitivity↓, cell proliferation, migration, invasion, glycolysis metabolism↑ | miR-488↓, HK2↑ | Q.Shi et al. (2023) [172] |
Human monocyte/macrophage cell line THP-1, human NSCLC lines A549 and H1299 | CircPLEKHM1 | NSCLC cell metastasis↑ | OSMR expression↑, m2 polarization of macrophages↑ | D.Wang et al. (2024) [173] |
LC tissues and paracancerous tissues, NSCLC cell lines (HCC1833, A549), male nude mice | CircFTO | Glycolysis and NSCLC progression↑ | miR-148a-3p↓, PDK4 expression↑ | Q.Liu et al. (2024) [174] |
Patient NSCLC tissues, Serum samples, NSCLC cell lines (H1650, PC9, H1299, and A549) | Circ-MEMO1 | Proliferation, cell cycle progression, glycolytic metabolism of NSCLC cells↑, the apoptosis of NSCLC cells↓ | miR-101-3p↓, KRAS level↓ | C.Ding et al. (2020) [177] |
Patient NSCLC tissues, Patient plasma, CD8 + T cell, NCI-H460, NCI-H1299, A549, PC9, 95D, HBE | Circ-USP7 | IFN-γ, TNF-α, Granzyme-B and Perforin secretion by CD8 + T cells↓; CD8 + T cell function↓; anti-PD1 immunotherapy resistance↑ | miR-934↓, SHP2 expression↑ | S.Chen et al. (2021) [179] |
NSCLC tissues, NSCLC cells (A549 and H1299) and human bronchial epithelial cells (16HBE; non-cancer cells) | Circ-0014235 | DDP chemoresistance↓, deteriorates the development of NSCLC | miR-520a-5p↓, CDK4↑ | X.Xu et al. (2020) [181] |
NSCLC A549/DDP and H1299/DDP cells | Circ-VMP1 | NSCLC progression and cisplatin (DDP) resistance↑ | miR-524-5p↓, METTL3/SOX2↑ | H.Xie et al. (2022) [182] |
Serum from NSCLC patients, human bronchial epithelial cells (BEAS-2B) and NSCLC cell lines (A549 and H292) | Circ-0076305 | Cisplatin (DDP) resistance of NSCLC↑ | miR-186-5p8↓, ABCC1↑ | X.Wang et al. (2023) [183] |
NSCLC and matched normal tissues, PC9GR and HCC827GR (gefitinib-resistant NSCLC cell lines) | Circ-KIF20B | Gefitinib resistance and cell proliferation↓ | miR-615-3p↓, MEF2A↑ | S.Wei et al. (2023) [184] |
NSCLC patients treated with EGFR-TKIs, the gefitinib sensitive cell lines PC9 and the corresponding gefitinib resistant cell lines PC9/GR, the erlotinib sensitive cell lines HCC827 and the corresponding erlotinib resistant cell lines HCC827/ER | Circ-102,481 | EGFR-TKIs resistance in NSCLC↑ | miR-30a-5p↓, ROR1↑ | B.Yang et al. (2021) [185] |
NSCLC tissues, A549, H1650, H460, H1299 from the NSCLC cell line along with 16 HBE-T from a cell line of human bronchial epithelial cell | Circ-100,395 | Malignant Transformation of NSCLC↓, epithelial mesenchymal transition↓ | miR-141-3p↓, LATS2 ↑ | C.Zhang et al. (2021) [186] |
NSCLC cells (A549 and H1299) and normal bronchial epithelial cells (BEAS-2B) | Circ-000735 | Non-small lung cancer malignant progression↑, epithelial mesenchymal transition↓ | miR-345‐5p↓, ADAM19↑ | S.Liu et al. (2023) [187] |
Patient plasma, Serum exosome isolation | Circ-0069313, Circ-0063526, Circ-0010522, Circ-0048677, Circ-0001946 | Hsa-circ-0069313 have the potential to discriminate NSCLC | None | Y.Chen et al. (2022) [188] |
Patients’ blood samples | Circ-0048856 | NSCLC development↑ | miR-1287–5p↓ | Y.He et al. (2022) [189] |
NSCLC patient plasma, serum exosome isolation | Circ-0047921, Circ-0056285, Circ-0007761 | Circ-0047921 could distinguish NSCLC cases from COPD controls, circ-0056285 and circ-007761 combination could distinguish NSCLC cases from tuberculosis controls | None | J.Xian et al. (2020) [190] |
Patient plasma, NSCLC cell line (NCI-H1299, A549, SPC-A-1, LTEP-A2, and Beas-2B) | Circ_0061407, Circ_0008103 | Proliferation, migration, invasion capabilities of NSCLC cells↓ | None | Z.Chen et al. (2024) [191] |
A549 and H2170 cell lines, Tanreqing | Circ-WDR78 | Proliferation and migration of NSCLC↓ | HIF1α↓ | W.Hong et al. (2023) [193] |